A detailed history of Price T Rowe Associates Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,097,599 shares of PRLD stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,097,599
Previous 891,298 23.15%
Holding current value
$1.05 Million
Previous $3.4 Million 33.09%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.07 - $6.37 $427,043 - $1.31 Million
206,301 Added 23.15%
1,097,599 $2.27 Million
Q2 2024

Aug 14, 2024

SELL
$3.32 - $5.63 $168,234 - $285,288
-50,673 Reduced 5.38%
891,298 $3.4 Million
Q1 2024

May 15, 2024

SELL
$2.68 - $4.84 $270,052 - $487,707
-100,766 Reduced 9.66%
941,971 $4.47 Million
Q4 2023

Feb 14, 2024

SELL
$1.69 - $4.37 $40,764 - $105,408
-24,121 Reduced 2.26%
1,042,737 $4.45 Million
Q3 2023

Nov 14, 2023

SELL
$2.74 - $4.79 $42,168 - $73,718
-15,390 Reduced 1.42%
1,066,858 $3.3 Million
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $3.55 Million - $6.48 Million
797,886 Added 280.59%
1,082,248 $4.87 Million
Q1 2023

May 15, 2023

SELL
$4.58 - $7.34 $74,722 - $119,752
-16,315 Reduced 5.43%
284,362 $1.62 Million
Q4 2022

Feb 14, 2023

SELL
$4.61 - $8.5 $57,569 - $106,148
-12,488 Reduced 3.99%
300,677 $1.82 Million
Q3 2022

Nov 14, 2022

BUY
$5.0 - $8.82 $29,060 - $51,261
5,812 Added 1.89%
313,165 $2.07 Million
Q2 2022

Aug 15, 2022

SELL
$4.0 - $7.55 $62,540 - $118,044
-15,635 Reduced 4.84%
307,353 $1.6 Million
Q1 2022

May 16, 2022

BUY
$6.9 - $13.22 $128,726 - $246,632
18,656 Added 6.13%
322,988 $2.23 Million
Q4 2021

Feb 14, 2022

SELL
$11.89 - $31.74 $1.08 Million - $2.89 Million
-90,944 Reduced 23.01%
304,332 $3.79 Million
Q3 2021

Nov 15, 2021

SELL
$25.78 - $38.65 $142,460 - $213,579
-5,526 Reduced 1.38%
395,276 $12.4 Million
Q2 2021

Aug 16, 2021

SELL
$28.63 - $44.3 $635,271 - $982,972
-22,189 Reduced 5.25%
400,802 $11.5 Million
Q1 2021

May 17, 2021

BUY
$39.27 - $91.68 $1.39 Million - $3.24 Million
35,311 Added 9.11%
422,991 $18.3 Million
Q4 2020

Feb 16, 2021

BUY
$28.81 - $88.94 $11.2 Million - $34.5 Million
387,680 New
387,680 $27.7 Million

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.9M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.